HUYA Bioscience International's Best New Drug Award (sponsored by HUYA Bioscience International) went to Sanofi Pasteur’s Dengvaxia (tetravalent dengue vaccine). Hugo Fry General Manager at Sanofi UK, speaks with Scrip after accepting the award.

Dengvaxia is the first vaccine against dengue, a disease that affects 390 million people each year. It is indicated to prevent dengue caused by all four of the virus serotypes and is the culmination of over two decades of scientific innovation and collaboration, with 40,000 volunteers participating in the development program.

The judges described it as an outstanding product that “clearly addresses a major medical need for a large number of poor people”.

свернуть